Stifel reiterates Hold rating on Philip Morris stock despite strong Q2

Philip Morris International reported robust second-quarter results, with over 18% constant currency EPS growth and nearly 15% operating profit growth, alongside 7% organic sales growth. Following this strong performance, the company raised its 2025 constant currency EPS growth outlook to 12.5% at the mid-point. Analysts, including Goldman Sachs and Citi, responded by raising price targets, driven by momentum in IQOS and improved ZYN supply, with future catalysts expected from IQOS ILUMA's U.S. launch.

Analysis

Philip Morris International demonstrated robust operational performance in its second quarter, delivering over 18% EPS growth and nearly 15% operating profit growth on a constant currency basis. This strength was underscored by a reported EPS of $1.91, which surpassed analyst estimates despite a larger-than-anticipated $0.04 foreign exchange headwind. Organic sales grew by nearly 7%, supported by volume growth of over 1%, signaling solid underlying demand. Consequently, management raised its 2025 guidance, now projecting constant currency EPS growth of 12.5% at the mid-point, a full percentage point increase. This positive outlook was met with a series of price target upgrades from Wall Street, including Goldman Sachs to $200, Citi to $200, and UBS to $181, citing momentum in the IQOS platform and easing supply constraints for ZYN. Key future catalysts include the anticipated U.S. launch of IQOS ILUMA post-FDA authorization and balance sheet improvement towards a 2x leverage target. However, potential headwinds exist, as the FDA's decision to allow Juul e-cigarettes to remain on the market could introduce competitive volatility, and some data signals suggest the stock's current valuation may be above its fair value.

Key Decisions for Investors

• Investors should weigh the company's strong operational momentum, evidenced by the double-digit constant currency earnings growth and upwardly revised 2025 guidance, as a primary driver for potential upside.
• It is critical to monitor progress on key upcoming catalysts, particularly the FDA authorization and commercial launch timeline for IQOS ILUMA in the U.S. and the sustained acceleration of ZYN sales as supply constraints ease.
• Despite the positive outlook, it is prudent to factor in potential risks from the competitive landscape, such as the FDA's recent Juul authorization, and to consider valuation, as some metrics suggest the stock may be fully priced.